Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daniel Chancellor

Advertisement
Set Alert for Articles By Daniel Chancellor

Latest From Daniel Chancellor

Opening The Door For Cell Therapy In Solid Tumors

The next frontier for cell therapy is solid tumors – and of the many attempts to move from liquid to solid tumors, tumor infiltrating lymphocytes and other CAR-T constructs are some of the most promising. 

Clinical Trials ImmunoOncology

PharmAI – Industry Is Smartening Up To Potential Of Artificial Intelligence

AstraZeneca’s pact with the UK-based artificial intelligence leader BenevolentAI, in April 2019, is one component in a string of recent deals that have highlighted big pharma’s desire to embed AI and machine learning within the R&D process. In total, 13 such collaborations have been tracked in the past 24 months, according to the Strategic Transactions database.

Artificial Intelligence Business Strategies

Two Years Of Artificial Intelligence Deals: A Pharma Snapshot

INFOGRAPHIC: major alliance deals focused on artificial intelligence and machine learning, signed by pharmaceutical companies over the past two years.

Artificial Intelligence Deals

Immuno-Oncology: Halfway To Adulthood

Almost a decade on since the first approval for an immuno-oncology therapy, In Vivo analyzes the current landscape, the evolution of combination cancer treatments that use the immune system to target disease and future commercial potential for the market.

ImmunoOncology Cancer
See All
Advertisement
UsernamePublicRestriction

Register